CALT - מחיר למכירות Calliditas Therapeutics, Inc.

Fundamental P/S reflects a phase of commercial growth for Calliditas Therapeutics following the launch of Tarpeyo and the expansion of its sales markets. Calliditas Therapeutics aims to establish the standard of care for IgA nephropathy to prevent kidney failure. The 7.10 mark indicates the current valuation of the business, which dominates the rare kidney disease niche due to the lack of effective alternatives for patients.

Calliditas Therapeutics (CALT) is strengthening its global presence through strategic alliances with STADA and Everest Medicines to expand its renal disease therapy. Analyzing the price-to-sales valuation, an investor observes the ratio of market capitalization to sales volume, which determines the price of each unit of revenue and reflects the balance between the business's fundamental value and market expectations for the company's future profits.